Barchart on MSN2h
This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.
There has been a shakeup in markets since Donald Trump’s election, and investors have been positioning their portfolios to ...
pharmaphorum23h
Vyndaqel romps away in US, spurring earnings hike from Pfizer
Pfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its first quarter on the market and looks set to quickly enter blockbuster territory.
JPMorgan says Pfizer needs further pipeline progress to change current narrative
After catching up with Pfizer’s Chairman and CEO, CFO, Chief Scientific Officer and Chief Strategy and Innovation Officer at the firm’s healthcare conference, JPMorgan analyst ...
CrowdStrike Stock Has Roared Back. Why This Trader Is 'Suspicious.'
CrowdStrike is back near highs despite crashing in July. Why Raymond James' David Cox calls it "immediately suspicious." ...
New Year, Same Bull. Why the Rally Isn’t Done.
Stocks have gotten off to a mixed start in 2025, but a third straight year of gains isn’t out of the question.